Methylation within the promoter region of JAM3 has been observed by certain scholars in 26.5% (13 out of 49) of precancerous lesions associated with esophageal carcinoma and in 51.1% (388 out of 760) of primary esophageal carcinomas, thereby modulating the expression of JAM3. Here, JAM3 is linked to carcinoma of esophagus.